Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Wayland Group Corp. (MRRCF)
Oakville, ON, CA
Wayland Group Corp. specializes in the cultivation and sale of both medical and recreational cannabis products, serving patients and consumers across Canada and on the international stage. Their product portfolio encompasses a diverse selection of cannabis strains, featuring varying levels of CBD, balanced cannabinoid profiles, and high THC content. These are marketed under several distinct brands, including Kiwi, Northern Harvest, High Tide, Lost at Seed, Solara C, Rare Dankness, and Maricann. Established in 2013, the company maintains its headquarters in Oakville, Canada, and operates as a subsidiary of Maricann Group Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +900.00% | +0.00% | -99.90% | -99.90% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-19.0%
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-341.2%
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-2,109.3%
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-2,077.9%
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-107.1%
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+85.0%
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.37×
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David Miller | Chief Financial Officer | — | male |
| Geoff Kosar | Vice President of Sales & Marketing | — | male |
| Graham Farrell | Vice President of Communications | — | male |
| James Hyssen | Chief Operating Officer | — | — |
| Raymond Howrad Stone | Secretary | — | male |
| Shawn Alexander | Vice President of Investor Relations | — | — |
| Steven Prescott Bennett | Chief Scientific Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MRRCF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
